This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Zykadia
  • /
  • LDK378 Versus Chemotherapy in Previously Untreated...
Clinical trial

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Read time: 2 mins
Last updated:1st Jul 2013
Identifier: NCT01828099

The primary purpose of the study is to compare the antitumor activity of LDK378 versus reference chemotherapy.

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
Enrollment: 374
Study Start Date: July 2013
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)

- Experimental:
- Active Comparator: Reference Chemotherapy

Related journal:
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Category Value
Date last updated at source 2016-11-03
Study type(s) Interventional
Expected enrolment 374
Study start date 2013-07-01
Estimated primary completion date 2018-06-01

View full details